Leucid Bio: the next generation of CAR T-cell therapies
July 31, 2025
CAR T-cell therapies hold the promise of curing solid tumour cancers. Dr John Maher, Chief Scientific Officer of Leucid Bio, explains how his biotech is
CAR T-cell therapies hold the promise of curing solid tumour cancers. Dr John Maher, Chief Scientific Officer of Leucid Bio, explains how his biotech is
WALTHAM, Mass. — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI® (pegcetacoplan) as the first treatment for
WALTHAM, Mass., — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced a capped royalty purchase agreement with Sobi® under which Apellis will receive up to $300
Southampton, UK – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company building a pipeline of innovative cyclic peptide and small molecule drugs to
Pioneering small-molecule program, NT-0796, targets chronic inflammation and its fundamental role in the complex cycle of weight regulation Oral, brain-penetrant NLRP3 inflammasome inhibitor being investigated
• Initiation of AERIAL trial accelerated by successful first close of Series A1 financing• LEU011 is first CAR-T candidate for the treatment of solid tumours
Apellis Pharmaceuticals, Inc. (APLS) has announced the immediate appointment of Craig Wheeler to its Board of Directors. Wheeler, the founder and CEO of Headwaters Biotech
Highlights LONDON, UK and Boston, MA, 7 April 2025 – Epsilogen, the global leader in the development of immunoglobulin E (IgE) antibody therapeutics, today announces
Dr Heather Preston, seasoned healthcare investor with over 30 years’ experience as a scientist, physician, management consultant, and Board adviser, joins as Chair Cambridge, UK,
WALTHAM, Mass. October 26, 2024 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® today announced that positive results from the Phase 3 VALIANT